K Kaku

Summary

Affiliation: Kawasaki Medical School
Country: Japan

Publications

  1. doi request reprint Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
    K Kaku
    Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan
    Diabetes Obes Metab 15:432-40. 2013
  2. pmc Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes
    Kohei Kaku
    Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan
    Diabetes Care 36:245-50. 2013
  3. doi request reprint Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus
    Kohei Kaku
    Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Curr Med Res Opin 27:73-84. 2011
  4. ncbi request reprint Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Endocr J 56:657-64. 2009
  5. ncbi request reprint Retained capacity of glucose-mediated insulin secretion in patients with type 2 diabetes mellitus inversely correlates with the duration of diabetes
    Kohei Kaku
    Department of Medicine, Endocrine and Diabetes Division, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Diabetes Res Clin Pract 64:221-3. 2004
  6. ncbi request reprint Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Endocr J 56:739-46. 2009
  7. doi request reprint Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
    K Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama 701 0192, Japan
    Diabetes Obes Metab 12:341-7. 2010
  8. doi request reprint Ablation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vascular endothelial cells enhances insulin sensitivity by reducing visceral fat and suppressing angiogenesis
    Kazuhito Tawaramoto
    Division of Diabetes, Endocrinology, and Metabolism, Kawasaki Medical School, Okayama 701 0192, Japan
    Mol Endocrinol 26:95-109. 2012
  9. doi request reprint Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
    K Kaku
    Diabetes and Endocrine Division, Kawasaki Medical School, Okayama, Japan
    Diabetes Obes Metab 13:1028-35. 2011
  10. ncbi request reprint Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Curr Med Res Opin 25:1111-9. 2009

Collaborators

Detail Information

Publications53

  1. doi request reprint Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
    K Kaku
    Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan
    Diabetes Obes Metab 15:432-40. 2013
    ..This study assessed the efficacy and safety of dapagliflozin monotherapy in Japanese T2DM patients with inadequate glycaemic control...
  2. pmc Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes
    Kohei Kaku
    Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan
    Diabetes Care 36:245-50. 2013
    ..Assessment of the efficacy and safety of TAK-875 (a novel GPR40 agonist) in Japanese patients with type 2 diabetes inadequately controlled by diet/exercise...
  3. doi request reprint Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus
    Kohei Kaku
    Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Curr Med Res Opin 27:73-84. 2011
    ..To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus...
  4. ncbi request reprint Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Endocr J 56:657-64. 2009
    ..Therefore mitiglinide effectively improves glycemic control in type 2 diabetic patients who are inadequately controlled by pioglitazone monotherapy...
  5. ncbi request reprint Retained capacity of glucose-mediated insulin secretion in patients with type 2 diabetes mellitus inversely correlates with the duration of diabetes
    Kohei Kaku
    Department of Medicine, Endocrine and Diabetes Division, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Diabetes Res Clin Pract 64:221-3. 2004
  6. ncbi request reprint Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Endocr J 56:739-46. 2009
    ..This drug combination therapy is a promising means of alleviating insufficient pancreatic insulin secretion and insulin resistance...
  7. doi request reprint Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
    K Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama 701 0192, Japan
    Diabetes Obes Metab 12:341-7. 2010
    ..Sulphonylureas (SUs) are often used as first-line treatments for type 2 diabetes in Japan, hence it is important to study new antidiabetic drugs in combination with SUs in Japanese patients...
  8. doi request reprint Ablation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vascular endothelial cells enhances insulin sensitivity by reducing visceral fat and suppressing angiogenesis
    Kazuhito Tawaramoto
    Division of Diabetes, Endocrinology, and Metabolism, Kawasaki Medical School, Okayama 701 0192, Japan
    Mol Endocrinol 26:95-109. 2012
    ..This demonstrates an unexpected role of PDK1 signaling in endothelial cells on the maintenance of proper glucose homeostasis through the regulation of adipocyte development...
  9. doi request reprint Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
    K Kaku
    Diabetes and Endocrine Division, Kawasaki Medical School, Okayama, Japan
    Diabetes Obes Metab 13:1028-35. 2011
    ..To assess the efficacy and safety of alogliptin added to pioglitazone versus pioglitazone monotherapy, in Japanese patients with type 2 diabetes who achieved inadequate glycaemic control on pioglitazone plus diet/exercise...
  10. ncbi request reprint Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Curr Med Res Opin 25:1111-9. 2009
    ..To assess the efficacy and safety of combination therapy with pioglitazone and metformin in Japanese patients with type 2 diabetes...
  11. ncbi request reprint Possible contribution of adipocytokines on diabetic neuropathy
    M Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki shi, Okayama ken 701 0192, Japan
    Diabetes Res Clin Pract 66:S121-3. 2004
    ..The present results suggest that adipocytokines may play a role not only on angiopathy but also on neuropathy in diabetics...
  12. pmc Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
    S Hamamoto
    Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan
    Diabetes Obes Metab 15:153-63. 2013
    ..We investigated the molecular mechanisms by which vildagliptin preserved pancreatic β cell mass and function...
  13. ncbi request reprint Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects
    M Matsuda
    Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki shi, Okayama, Japan
    Diabet Med 21:881-8. 2004
    ....
  14. ncbi request reprint Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages
    Y Iwashima
    Department of Internal Medicine, Sano Hospital, Suehiro 3 3 1 15, Asahikawa, 078 8133, Japan
    Biochem Biophys Res Commun 277:368-80. 2000
    ..Thus, AGEs may be involved in the cause of variable levels of foam cell formation via the increased numbers of OxLDL receptors in accelerated atherosclerotic lesions of individuals with diabetes...
  15. ncbi request reprint Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice
    Fumiko Kawasaki
    Diabetes and Endocrine Division, Dept of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki shi, Okayama ken 701 0192, Japan
    Am J Physiol Endocrinol Metab 288:E510-8. 2005
    ..Our results suggest that pioglitazone improves glucolipotoxicity by increasing insulin sensitivity and reducing fat accumulation in the pancreatic islets...
  16. ncbi request reprint Downregulation of the voltage-dependent calcium channel (VDCC) beta-subunit mRNAs in pancreatic islets of type 2 diabetic rats
    Y Iwashima
    Department of Internal Medicine, Sano Hospital, Suehiro 3 3 1 15, Asahikawa 078 8133, Japan
    Biochem Biophys Res Commun 280:923-32. 2001
    ....
  17. ncbi request reprint Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes
    Mieko Saito
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Metabolism 51:964-9. 2002
    ..RLP from apo E2/2 diabetes with type III HLP are more atherogenic than those from apo E2/2 nondiabetes with type III HLP...
  18. ncbi request reprint Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease
    M Hamano
    Clinical Laboratory, Kawasaki Medical School, Kurashiki 701 0192, Japan
    Ann Clin Biochem 41:125-9. 2004
    ..We assessed the association of CHD with SAA, CRP and RLP-cholesterol in type 2 diabetic patients...
  19. pmc The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
    M Shimoda
    Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Diabetologia 54:1098-108. 2011
    ..We investigated the molecular mechanism by which the human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice...
  20. ncbi request reprint Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers
    K Kaku
    Department of Medicine, Diabetes Division, Kawasaki Medical School, 577 Matsushima, 701 0192, Kurashiki, Japan
    Diabetes Res Clin Pract 49:119-26. 2000
    ....
  21. doi request reprint Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity
    Kohei Kaku
    Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Curr Med Res Opin 25:2925-32. 2009
    ..To evaluate the efficacy of pioglitazone for the prevention of macrovascular outcomes in Japanese patients with type 2 diabetes, without a recent history of macrovascular morbidity...
  22. ncbi request reprint Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients
    Masaaki Eto
    Department of Medicine, Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Am J Kidney Dis 40:243-51. 2002
    ..The aim of the present study is to further investigate the association between apo E genetic polymorphism, plasma lipid levels (particularly remnant lipoproteins), and diabetic nephropathy...
  23. ncbi request reprint [Repaglinide (NN-623)]
    Masafumi Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School
    Nihon Rinsho 60:555-8. 2002
  24. ncbi request reprint Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes
    Masafumi Matsuda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama ken 701 0192
    Eur J Pharmacol 453:141-8. 2002
    ..Our results strongly suggest the possibility that chronic intervention with an ATP-sensitive K(+) channel opener prevents the progress of deranged beta-cell function even after the development of diabetes mellitus...
  25. ncbi request reprint Gallbladder edema in type 1 diabetic patient due to delayed-type insulin allergy
    Fumiko Kawasaki
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School, Kurashiki
    Intern Med 48:1545-9. 2009
    ..Furthermore, tests revealed increased VEGF levels. This is an extremely rare case with a delayed-type protamine allergy caused by NovolinN resulting in gallbladder edema...
  26. doi request reprint Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance
    Ryuzo Kawamori
    Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan
    Lancet 373:1607-14. 2009
    ..We therefore assessed whether voglibose, an alpha-glucosidase inhibitor, could prevent the development of type 2 diabetes in high-risk Japanese individuals with impaired glucose tolerance...
  27. ncbi request reprint Analysis of waist circumference in Japanese subjects with type 2 diabetes mellitus: lack of propriety to define the current criteria of metabolic syndrome
    Yukiko Kanda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    Diabetes Res Clin Pract 77:S220-3. 2007
    ..Further prospective analysis should be required to validate the criteria and clinical significance of MetS in T2DM...
  28. ncbi request reprint Molecular analysis of db gene-related pancreatic beta cell dysfunction; evidence for a compensatory mechanism inhibiting development of diabetes in the db gene heterozygote
    Yukiko Kanda
    Diabetes and Endocrine Division, Department of Internal Medicine, Kawasaki Medical School, Kurashiki 701 0192, Japan
    Endocr J 56:997-1008. 2009
    ..The present results strongly suggest that the db gene heterozygote, but not homozygote, acquires a compensatory mechanism suppressing beta-cell apoptosis and augmenting the capacity of beta-cell function...
  29. ncbi request reprint Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing
    Michihiro Matsuki
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Endocr J 54:571-6. 2007
    ..Analyses of adverse events and laboratory data demonstrated a favorable safety profile of glimepiride. The present results suggest that glimepiride may be suitable for once-daily dosing with respect to clinical usefulness...
  30. ncbi request reprint Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients
    Mieko Saito
    Diabetes and Endocrine Division, Department of Internal Medicine, Kawasaki Medical School, Matsushima 577, Kurashiki 701 0192, Japan
    Diabetes Care 27:1276-80. 2004
    ..The aim of this study was to investigate the effect of apolipoprotein (apo)E4 allele on plasma LDL cholesterol response to calorie-restricted diet therapy in type 2 diabetic patients...
  31. ncbi request reprint First phase of glucose-stimulated insulin secretion from MIN 6 cells does not always require extracellular calcium influx
    Makoto Shigeto
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
    J Pharmacol Sci 101:293-302. 2006
    ....
  32. doi request reprint GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes
    T Araki
    Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan
    Diabetes Obes Metab 14:271-8. 2012
    ..In this study, we present the first clinical data for TAK-875, a novel highly selective, orally bioavailable GPR40 agonist, in Japanese patients with type 2 diabetes insufficiently controlled by diet or exercise therapy...
  33. pmc Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist
    Yukiko Kanda
    Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, Japan
    Am J Physiol Endocrinol Metab 298:E278-86. 2010
    ....
  34. ncbi request reprint [Insulin detemir (NN304)]
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School
    Nihon Rinsho 60:511-5. 2002
  35. ncbi request reprint [Drug-induced hypoglycemia]
    Mitsuru Hashiramoto
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
    Nihon Rinsho 65:575-83. 2007
  36. ncbi request reprint Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan
    M Eto
    Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    Clin Genet 61:416-22. 2002
    ..The patients were characterized by a high frequency of obesity and/or glucose intolerance. The TG-rich lipoproteins from type III HLP patients with diabetes mellitus were more atherogenic...
  37. ncbi request reprint [Role of glycemic control on preventing diabetic macroangiopathy and its therapeutic guidance]
    Fuminori Tatsumi
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
    Nihon Rinsho 68:892-7. 2010
    ..However, the concrete target of glycemic control to prevent macroangiopathy is still controversial. In this article, we reviewed recent clinical trials from the viewpoint of glycemic control and prevention of diabetic macroangiopathy...
  38. ncbi request reprint [Soluble long-acting human insulin analog--action profile and clinical application]
    Kohei Kaku
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School
    Nihon Rinsho 60:498-502. 2002
  39. ncbi request reprint Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum
    Makoto Shigeto
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama 701 0192, Japan
    J Pharmacol Exp Ther 322:1-7. 2007
    ..We also demonstrated that the latter pathway involves the intracellular calcium release from endoplasmic reticulum via ryanodine receptor activation...
  40. doi request reprint Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone
    Yukiko Kanda
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki shi, Okayama ken 701 0192, Japan
    Diabetes Res Clin Pract 81:13-8. 2008
    ..The significance of the extrapancreatic action of SUs observed in this study should be further evaluated in the clinical field...
  41. ncbi request reprint Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway
    Makoto Shigeto
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan
    J Pharmacol Sci 108:274-9. 2008
    ..Studies of GLP-1 at physiologic concentrations may lead to new developments in studies of pancreatic beta-cell function...
  42. ncbi request reprint MIN6 is not a pure beta cell line but a mixed cell line with other pancreatic endocrine hormones
    Koji Nakashima
    Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School, Okayama, Japan
    Endocr J 56:45-53. 2009
    ..The present study clearly demonstrated that MIN6 produce pancreatic endocrine cells. It would be possible to use this cell line as a model to research the development, cell differentiation and function of pancreatic islets...
  43. ncbi request reprint [A target of PPARgamma agonist: diabetes mellitus]
    Mitsuru Hashiramoto
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
    Nihon Rinsho 68:284-93. 2010
    ..A number of studies have also proven the potency of PPARgamma agonists in the prevention of onset of T2DM...
  44. doi request reprint The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance
    Muhammad A Abdul-Ghani
    Diabetes Division, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Am J Physiol Endocrinol Metab 295:E401-6. 2008
    ....
  45. pmc Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes
    Akio Kanazawa
    Laboratory for Diabetic Nephropathy, SNP Research Center, The Institute of Physical and Chemical Research, Kanagawa, Japan
    Am J Hum Genet 75:832-43. 2004
    ..These results indicate that the WNT5B gene may contribute to conferring susceptibility to type 2 diabetes and may be involved in the pathogenesis of this disease through the regulation of adipocyte function...
  46. ncbi request reprint Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus
    Shiro Maeda
    Laboratory for Diabetic Nephropathy, SNP Research Center, The Institute of Physical and Chemical Research, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa, 230 0045, Japan
    J Hum Genet 50:283-92. 2005
    ..These results suggest that TFAP2B might be a new candidate for conferring susceptibility to type 2 diabetes and contribute to the pathogenesis of type 2 diabetes...
  47. ncbi request reprint Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms
    Nobue Tanaka
    Laboratory for Diabetic Nephropathy, SNP Research Center, The Institute of Physical and Chemical Research, Yokohama, Kanagawa, Japan
    Diabetes 52:2848-53. 2003
    ....
  48. ncbi request reprint [Progress in chemotherapy of type 2 diabetes mellitus]
    Kohei Kaku
    Nihon Naika Gakkai Zasshi 96:505-9. 2007
  49. ncbi request reprint [Case of familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis with ABCAlexon 4 minus transcript in macrophages]
    Mieko Saito
    Moleculan Biology Kawasaki Medical School, Kurashiki
    Nihon Naika Gakkai Zasshi 91:2762-4. 2002
  50. ncbi request reprint Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy
    Atsuyuki Shimazaki
    SNP Research Center, The Institute of Physical and Chemical Research, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    Diabetes 54:1171-8. 2005
    ..These results indicate that ELMO1 is a novel candidate gene that both confers susceptibility to DN and plays an important role in the development and progression of this disease...
  51. ncbi request reprint Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population
    Shintaro Omori
    Laboratory for Diabetic Nephropathy, SNP Research Center, RIKEN, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    Diabetes 57:791-5. 2008
    ....
  52. ncbi request reprint Polymorphisms in the 3' UTR in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy
    Masumi Kamiyama
    Laboratory for Diabetic Nephropathy, SNP Research Centre, Institute of Physical and Chemical Research, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    Hum Genet 122:397-407. 2007
    ..G, P = 0.03, odds ratio = 1.91, 95% CI 1.07-3.42). These results suggest that the NCALD gene is a likely candidate for conferring susceptibility to diabetic nephropathy...
  53. ncbi request reprint [Treatment for patients with impaired glucose tolerance]
    Kazuhito Tawaramoto
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Kawasaki Medical School
    Nihon Rinsho 63:423-7. 2005